A Randomized Controlled Clinical Study of Tofacitib versus Etanercept in the Treatment of Active Ankylosing Spondylitis
Objective To explore the therapeutic effects of controlled tofacitib and etanercept in active ankylosing spondylitis.Methods A total of 70 patients with active ankylosing spondylitis who received treatment in Heze Munici-pal Hospital from June to December 2023 were selected as the study objects and were divided into two groups accord-ing to the medication regimens.Patients in the control group were treated with etanercept injection therapy,and pa-tients in the observation group were treated with tofacitib.The efficacy,inflammatory indexes and prognosis of the two groups were compared.Results There was no statistically significant difference in total effective rate between the two groups(93.33%vs 96.67%)(χ2=0.351,P>0.05).There were no statistically significant differences in the blood sedi-mentation rate,C-reactive protein and tumor necrosis factor-α levels between the two groups(all P>0.05).There was no statistically significant difference in Visual Analogue Scale scores,Bath Ankylosing Spondylitis Disease Activity In-dex and Bath Ankylosing Spondylitis Functional Index between the two groups(all P>0.05).Conclusion Tofacitib and etanercept in the treatment of active ankylosing spondylitis are able to ensure the overall efficacy,can be effective anti-inflammatory,and can play a positive role in reducing the pain of patients and improving their prognosis,and can be selected according to the specific circumstances of the treatment program.
Active ankylosing spondylitisTofacitibEtanerceptOverall efficacyInflammatory indicators
万方数据
维普
